<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35294549</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Accumulation of Nonfibrillar TDP-43 in the Rough Endoplasmic Reticulum Is the Early-Stage Pathology in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>271</StartPage><EndPage>281</EndPage><MedlinePgn>271-281</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlac015</ELocationID><Abstract><AbstractText>Transactivation response DNA-binding protein 43 (TDP-43)-immunoreactive neuronal cytoplasmic inclusions (NCIs) are the histopathological hallmarks of amyotrophic lateral sclerosis (ALS). They are classified as skein-like inclusions, round inclusions, dot-like inclusions, linear wisps, and diffuse punctate cytoplasmic staining (DPCS). We hypothesized that TDP-43-immunoreactive DPCS may form the early-stage pathology of ALS. Hence, we investigated phosphorylated TDP-43 pathology in the upper and lower motor neurons of patients with ALS and control participants. We designated patients whose disease duration was &#x2264;1&#x2009;year as short-duration ALS (n&#x2009;=&#x2009;7) and those whose duration equaled 3-5&#x2009;years as standard-duration ALS (n&#x2009;=&#x2009;6). DPCS and skein-like inclusions were the most common NCIs in short-duration and standard-duration ALS, respectively. The density of DPCS was significantly higher in short-duration ALS than that in standard-duration ALS and was inversely correlated with disease duration. DPCS was not ubiquitinated and disappeared after proteinase K treatment, suggesting that it was not aggregated. Immunoelectron microscopy revealed that DPCS corresponded to nonfibrillar TDP-43 localized to the ribosomes of the rough endoplasmic reticulum (ER). These findings suggest that nonfibrillar TDP-43 accumulation in the rough ER is the earliest TDP-43 pathology in ALS, which may be helpful in developing future TDP-43 breakdown strategies for ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 American Association of Neuropathologists, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kon</LastName><ForeName>Tomoya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6072-3954</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Fumiaki</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanji</LastName><ForeName>Kunikazu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miki</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishijima</LastName><ForeName>Haruo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Iku</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Chieko</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurotaki</LastName><ForeName>Hidekachi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Aomori Prefectural Central Hospital, Aomori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomiyama</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wakabayashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018870" MajorTopicYN="Y">Endoplasmic Reticulum, Rough</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Diffuse punctate cytoplasmic staining</Keyword><Keyword MajorTopicYN="N">Morphology</Keyword><Keyword MajorTopicYN="N">Ribosome</Keyword><Keyword MajorTopicYN="N">Rough endoplasmic reticulum</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>16</Day><Hour>17</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35294549</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlac015</ArticleId><ArticleId IdType="pii">6549725</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>